Local rhamnosoft, ceramides and L-isoleucine in atopic eczema: A randomized, placebo controlled trial

Pediatric Allergy and Immunology

Volumn 25, Issue 3, 2014, Pages 271-275

  Marseglia, Alessia ^a   Licari, Amelia ^a   Agostinis, Fabio ^b   Barcella, Antonio ^b   Bonamonte, Domenico ^c   Puviani, Mario ^d   Milani, Massimo ^e   Marseglia, Gianluigi ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Servizio di Dermatologia   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d Ospedale di Sassuolo   (Italy)

^e Isdin Medical Department   (Italy)

Author keywords

Assessor blinded; Atopic eczema; Emollient therapy; Randomized trial

Indexed keywords

CALCINEURIN INHIBITOR; CERAMIDE; DERMATOLOGICAL AGENT; EMOLLIENT AGENT; ISOLEUCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROAMP CREAM; RHAMNOSE; STEROID; UNCLASSIFIED DRUG; DRUG COMBINATION; OINTMENT; POLYSACCHARIDE;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FACE; FACIAL ECZEMA SEVERITY SCORE; FEMALE; HUMAN; INFANT; LICHENOID ERUPTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCRATCHING; SINGLE BLIND PROCEDURE; CLINICAL TRIAL; DRUG COMBINATION; ECZEMA; OINTMENT; PRESCHOOL CHILD;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CERAMIDES; CHILD, PRESCHOOL; DRUG COMBINATIONS; ECZEMA; FEMALE; HUMANS; INFANT; ISOLEUCINE; MALE; OINTMENTS; POLYSACCHARIDES; PROSPECTIVE STUDIES; RHAMNOSE;

EID: 84898809864     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12185     Document Type: Article

References (35)

1. Shen CY, Lin MC, Lin HK, Lin CH, Fu LS, Fu YC. The natural course of eczema from birth to age 7 years and the association with asthma and allergic rhinitis: a population-based birth cohort study. Allergy Asthma Proc 2013: 34: 78-83.
2. Burr ML, Dunstan FD, Hand S, Ingram JR, Jones KP. The natural history of eczema from birth to adult life: a cohort study. Br J Dermatol 2013: 168: 1339-42.
3. Darsow U, Wollenberg A, Simon D, et al. ETFAD, EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010: 24: 317-28.
4. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008: 121: 1337-43.
5. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002: 347: 1151-60.
6. Jinnestål CL, Belfrage E, Bäck O, Schmidtchen A, Sonesson A. Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in adult patients with atopic dermatitis. Int J Dermatol 2014: 53: 27-33.
7. Bieber T. Atopic dermatitis. N Engl J Med 2008: 358: 1483-94.
8. Lee NP, Arriola ER. Topical corticosteroids: back to basics. West J Med 1999: 171: 351-3.
9. Andrès E, Molinari J, Péterszegi G, et al. Pharmacological properties of rhamnose-rich polysaccharides, potential interest in age-dependent alterations of connectives tissues. Pathol Biol (Paris) 2006: 54: 420-5.
10. Jungersted JM, Agner T. Eczema and ceramides: an update. Contact Dermatitis 2013: 69: 65-71.
11. Sherman H, Chapnik N, Froy O. Albumin and amino acids upregulate the expression of human beta-defensin 1. Mol Immunol 2006: 43: 1617-23.
12. Fehlbaum P, Rao M, Zasloff M, Anderson GM. An essential amino acid induces epithelial beta-defensin expression. Proc Natl Acad Sci U S A 2000: 97: 12723-8.
13. Tyrrell C, De Cecco M, Reynolds NL, et al. Isoleucine/leucine 2 is essential for chemoattractant activity of beta-defensin Defb 14 through chemokine receptor 6. Mol Immunol 2010: 47: 1378-82.
14. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980: 92: 44-7.
15. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001: 10: 11-8.
16. Gelmetti C, Colonna C. The value of SCORAD and beyond. Towards a standardized evaluation of severity? Allergy 2004: 59(Suppl. 78): 61-5.
17. Elias PM, Feingold KR. Lipids and the epidermal water barrier: metabolism, regulation, and pathophysiology. Semin Dermatol 1992: 11: 176-82.
18. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol 2008: 17: 1063-72.
19. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol 2009: 9: 437-46.
20. Imokawa G, Abe A. decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 1991: 96: 523-6.
21. O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2008: 122: 689-93.
22. Gupta J, Grube E, Ericksen MB, et al. Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity. J Allergy Clin Immunol 2008: 121: 725-30.
23. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 2001: 137: 1079-81.
24. Hon KL, Leung AK, Barankin B. barrier repair therapy in atopic dermatitis: an overview. Am J Clin Dermatol 2013: 14: 389-99.
25. Nolan K, Marmur E. Moisturizers: reality and the skin benefits. Dermatol Ther 2012: 25: 229-33.
26. Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol 2013: 31: 91-8.
27. Rubel D, Thirumoorthy T. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol 2013: 40: 160-71.
28. Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007: 214: 61-7.
29. Gelmetti C, Boralevi F, Seité S, et al. Quality of life of parents living with a child suffering from atopic dermatitis before and after a 3-month treatment with an emollient. Pediatr Dermatol 2012: 29: 714-8.
30. Patrizi A, Capitanio B, Neri I, et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol 2008: 19: 619-25.
31. Hon KL, Pong NH, Wang SS, Lee VW, Luk NM, Leung TF. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D 2013: 13: 37-42.
32. Elias PM, Wakefield JS. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clin Rev Allergy Immunol 2011: 41: 282-95.
33. Simpson E, Böhling A, Bielfeldt S, Bosc C, Kerrouche N. Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. J Dermatolog Treat 2013: 24: 122-5.
34. Draelos ZD. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis. J Cosmet Dermatol 2011: 10: 185-8.
35. Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011: 10: 531-7.